We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Justices will consider whether the law permits the waiver of future claims against parties not in bankruptcy
A court ruling clears the way for swift payment for those affected by the US opioid crisis
Appeals court says some liability releases are ‘appropriate’ under US bankruptcy law
Decision comes at end of review instigated by new vice-chancellor Irene Tracey
Documents show privileged access to the Boat Race and continued acceptance of donations
Congressional probe found 22 consultants had advised both the US FDA and drug manufacturers over a decade
Members of Sackler family who owned OxyContin maker will increase financial contribution but still receive a legal shield
Proposal revealed by court mediator comes after a judge rejected earlier deal
It is unfortunate that critics of the current system have not articulated a better one for the aggrieved
Sackler family was to make multibillion-dollar contribution in exchange for protection from lawsuits
Move is the latest fallout for members of the family that owned opioid maker Purdue Pharma
Writer Beth Macy and director Barry Levinson discuss taking on the Sacklers and victim-blaming in their mini-series
Judge approves bankruptcy plan for opioid maker in which family will pay $4.5bn
Critics say concessions in case regarding the company diminishes accountability in overdose scandal
Agreement with holdouts brings US drugmaker a step closer to emerging from bankruptcy
Patrick Radden Keefe’s saga of how a pharmaceutical dynasty unleashed a wave of dependency and grew rich from it
Agreement brings consultancy’s total bill for prescription painkiller advice to $619m
Owners of opioid maker Purdue Pharma pledge extra money to win over US states that rejected deal
Answers emerge as to the unexplained departures from the consultancy’s investment banking research unit
My former consultancy demonstrates what is wrong with business school graduates
After settling opioid crisis-related claims and separately firing two partners, the consultancy weighs its next move
Consultancy not likely to admit wrongdoing or liability over its advising of drug companies
Two former board members tell Congress they do not bear personal responsibility for addiction epidemic
Investigators must bring to book the highest profile perpetrators
Punitive actions do not just exact narrow justice — they serve as a deterrent against future misdeeds
International Edition
